WuXi XDC Cayman, Inc. (HK:2268)
:2268
Want to see HK:2268 full AI Analyst Report?
2268 Stock Chart & Stats
HK$54.80
HK$1.55(5.24%)
At close: 4:00 PM EST
HK$54.80
HK$1.55(5.24%)
Day’s Range― - ―
52-Week RangeHK$35.60 - HK$85.50
Previous CloseN/A
Volume4.11M
Average Volume (3M)6.66M
Market Cap
HK$67.32B
Enterprise ValueHK$62.54B
Total Cash (Recent Filing)HK$7.47B
Total Debt (Recent Filing)HK$879.52M
Price to Earnings (P/E)23.2
Beta1.08
Next Earnings
Aug 25, 2026EPS Estimate
0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.20
Shares Outstanding1,260,609,400
10 Day Avg. Volume10,688,598
30 Day Avg. Volume6,656,062
Financial Highlights & Ratios
PEG Ratio1.31
Price to Book (P/B)6.72
Price to Sales (P/S)12.13
P/FCF Ratio113.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$82.67Price Target Upside50.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.63
Revenue Forecast (FY)HK$8.13B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthConsistent top-line expansion—revenue reached 5.79B in 2025 (+13.8% YoY) after multiple years of rapid expansion—signals sustained client demand and successful customer program progression. That trend supports higher GMP capacity utilization and strengthens pricing leverage over the medium term.
High Profitability MarginsRobust operating and net margins reflect strong pricing power and operational efficiency in specialized ADC services. Sustainable margins support reinvestment in GMP facilities, fund R&D and process improvements, and provide a durable cushion against cyclical dips in customer demand.
Conservative Balance SheetVery low leverage and substantial equity provide financial flexibility to invest in capacity expansion, absorb program timing variability, and pursue strategic initiatives without material refinancing risk. This resilience enhances long‑term operational stability in a lumpy CDMO market.
Bears Say
Volatile Cash ConversionFree cash flow has been inconsistent, with a large negative year in 2024 and only modest FCF in 2025 (~34% of net income). Uneven cash conversion can constrain discretionary capital allocation, slow capacity builds, and force dependence on external financing when customer billings or milestone timings shift.
Margin CompressionReported margin compression versus the prior year suggests rising cost intensity as the business scales. Persistent higher input, labor or compliance costs—or increased competitive pricing pressure—could limit margin recovery and reduce the company’s ability to fund organic growth from operating profits.
Concentration In ADC CDMO MarketThe company's niche focus on ADC discovery, development and GMP services concentrates revenue on a subset of biotech programs. This specialization increases exposure to program timing, clinical setbacks, or customer consolidation, heightening revenue cyclicality and limiting diversification of demand sources.
WuXi XDC Cayman, Inc. News
2268 FAQ
What was WuXi XDC Cayman, Inc.’s price range in the past 12 months?
WuXi XDC Cayman, Inc. lowest stock price was HK$35.60 and its highest was HK$85.50 in the past 12 months.
What is WuXi XDC Cayman, Inc.’s market cap?
WuXi XDC Cayman, Inc.’s market cap is HK$67.32B.
When is WuXi XDC Cayman, Inc.’s upcoming earnings report date?
WuXi XDC Cayman, Inc.’s upcoming earnings report date is Aug 25, 2026 which is in 96 days.
How were WuXi XDC Cayman, Inc.’s earnings last quarter?
WuXi XDC Cayman, Inc. released its earnings results on Mar 23, 2026. The company reported HK$0.699 earnings per share for the quarter, missing the consensus estimate of HK$0.711 by -HK$0.011.
Is WuXi XDC Cayman, Inc. overvalued?
According to Wall Street analysts WuXi XDC Cayman, Inc.’s price is currently Undervalued.
Does WuXi XDC Cayman, Inc. pay dividends?
WuXi XDC Cayman, Inc. does not currently pay dividends.
What is WuXi XDC Cayman, Inc.’s EPS estimate?
WuXi XDC Cayman, Inc.’s EPS estimate is 0.89.
How many shares outstanding does WuXi XDC Cayman, Inc. have?
WuXi XDC Cayman, Inc. has 1,260,609,400 shares outstanding.
What happened to WuXi XDC Cayman, Inc.’s price movement after its last earnings report?
WuXi XDC Cayman, Inc. reported an EPS of HK$0.699 in its last earnings report, missing expectations of HK$0.711. Following the earnings report the stock price went down -4.06%.
Which hedge fund is a major shareholder of WuXi XDC Cayman, Inc.?
Currently, no hedge funds are holding shares in HK:2268
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
WuXi XDC Cayman, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$82.67 (50.86% Upside)
HK$82.67 (50.86% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
226.79%
12-Months-Change
Fundamentals
Return on Equity
16.16%
Trailing 12-Months
Asset Growth
65.58%
Trailing 12-Months
Company Description
WuXi XDC Cayman, Inc.
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
2268 Stock 12 Month Forecast
Average Price Target
HK$82.67
▲(50.86% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---